title: Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?
authors.affiliation: Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Dorothy E
authors.initials: DE
authors.lastname: Scott
authors.affiliation: Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Jay S
authors.initials: JS
authors.lastname: Epstein
mesh_terms: D000017:ABO Blood-Group System; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000017:ABO Blood-Group System; D016756:Immunoglobulins, Intravenous